07:00 , Aug 2, 2012 |  BC Innovations  |  Strategy

AZ goes APOE

AstraZeneca plc has assembled an academia-industry consortium to unravel the role of apolipoprotein E in Alzheimer's disease. The team, dubbed the A5 alliance, hopes to uncover basic mechanisms about how apolipoprotein E drives the disease...
08:00 , Mar 1, 2012 |  BC Innovations  |  Targets & Mechanisms

APOE in AD

U.S. researchers have shown that Eisai Co. Ltd. 's cancer drug Targretin bexarotene raises apolipoprotein E levels in the brain and partially reverses cognitive and behavioral deficits in a mouse model of Alzheimer's disease. 1...